{"id":"NCT00069121","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer","officialTitle":"An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) (\"XELOX\") Versus Fluorouracil/Leucovorin as Adjuvant Therapy for Patients Who Have Undergone Surgery for Colon Carcinoma, AJCC/UICC Stage III (Dukes Stage C)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-04-18","primaryCompletion":"2011-04-21","completion":"2011-04-21","firstPosted":"2003-09-18","resultsPosted":"2011-07-29","lastUpdate":"2020-03-06"},"enrollment":1886,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Colorectal Cancer"],"interventions":[{"type":"DRUG","name":"Capecitabine","otherNames":["Xeloda"]},{"type":"DRUG","name":"Oxaliplatin","otherNames":[]},{"type":"DRUG","name":"Leucovorin (LV)","otherNames":[]},{"type":"DRUG","name":"5-Fluorouracil (5-FU)","otherNames":[]}],"arms":[{"label":"5-Fluorouracil/Leucovorin (5-FU/LV)","type":"ACTIVE_COMPARATOR"},{"label":"Capecitabine in Combination with Oxaliplatin (XELOX)","type":"EXPERIMENTAL"}],"summary":"This 2 arm study will compare the efficacy and safety of intermittent oral Xeloda plus Eloxatin (oxaliplatin) with that of fluorouracil/leucovorin in patients who have had surgery for colon cancer and no previous chemotherapy. Patients will be randomized to receive either 1) XELOX (Xeloda 1000mg/m2 po bid on days 1-15 + oxaliplatin) in 3 week cycles or 2)5-fluorouracil + leucovorin in 4 or 8 week cycles. The anticipated time on study treatment is until disease progression and the target sample size is 500+ individuals.","primaryOutcome":{"measure":"Disease-Free Survival (DFS) [Number of Events]","timeFrame":"Time from randomization date to date of first DFS event/date last known to be event-free. Median observation time for DFS was 74 months (range: 0-95 months).","effectByArm":[{"arm":"5-FU/LV","deltaMin":379,"sd":null},{"arm":"XELOX","deltaMin":320,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":232,"countries":["United States","Australia","Belgium","Brazil","Canada","China","Finland","France","Germany","Greece","Hong Kong","Hungary","Ireland","Israel","Italy","Mexico","New Zealand","Panama","Poland","Portugal","Russia","Singapore","South Africa","South Korea","Spain","Switzerland","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":["36306483","26324362"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":134,"n":657},"commonTop":["DIARRHOEA","NAUSEA","STOMATITIS ALL","VOMITING","FATIGUE"]}}